What Is DAC in Peptides?

Published August 2026 · Patriot Labs Research Team · ~14 min read

DAC stands for Drug Affinity Complex, and it is not a peptide. It is a bolt-on chemical modification: a short chemical arm ending in a reactive group called a maleimide is built onto the peptide, and once in circulation that maleimide latches permanently onto a specific site on serum albumin — the most abundant protein in blood. The peptide is now riding a carrier that the body keeps in circulation for weeks instead of minutes.

The result is a molecule with the same biological message but a completely different delivery schedule. A GHRH analog that would have been cleared in minutes instead signals for days. That single change is why CJC-1295 with DAC and CJC-1295 without DAC are treated as two different research tools despite sharing a nearly identical active core. The rest of this guide explains exactly how that works and what it means in practice.

The problem DAC was invented to solve

Peptides make attractive research molecules for the same reason they make frustrating ones. They are precise — a short chain of amino acids that fits a receptor the way a key fits a lock — but the body treats them as food, not furniture. Two clearance mechanisms dominate:

Enzymatic degradation. Blood and tissue are full of peptidases whose job is to cut peptide bonds. One of the best-characterized, dipeptidyl peptidase-4 (DPP-4), clips two residues off the front end of any peptide with a susceptible amino acid in the second position. Natural growth-hormone-releasing hormone is exactly that kind of substrate, which is why native GHRH survives roughly seven minutes in plasma before it is chewed into an inactive fragment.

Renal filtration. The kidney's glomerulus acts as a molecular sieve, freely filtering anything much smaller than about 45–60 kilodaltons. A 29-amino-acid peptide weighs roughly 3.4 kDa — more than an order of magnitude below the cutoff. It passes straight through and out.

Chemists have several ways to fight this. You can substitute unnatural amino acids at the cleavage sites so the enzymes cannot get a grip. You can hang a polyethylene-glycol chain on the molecule (PEGylation) to bulk it up past the filtration threshold. Or you can do what the DAC platform does: attach the peptide to a protein the body has already decided to keep. That last approach has an elegance the others lack — it borrows an existing biological system rather than fighting one.

The chemistry: what DAC actually is

A DAC-modified peptide has three functional parts, and it is worth separating them because people often collapse all three into the abbreviation:

1. The active peptide. The original molecule, usually with a few amino acid substitutions to make it more chemically rugged. Its job is unchanged: bind its receptor and deliver its signal.
2. The linker. A short spacer arm, typically attached at a lysine side chain, that holds the reactive end far enough from the peptide body that binding to a large protein does not sterically smother the active region.
3. The reactive group. A maleimide — in the classic DAC design, a maleimidopropionyl group. Maleimides are “soft electrophiles” that react specifically and rapidly with thiols (–SH groups), forming a stable thioether bond in a reaction chemists call Michael addition.

The clever part is the selectivity. Blood contains many thiol-bearing molecules — free cysteine, glutathione, other proteins — so why does the maleimide find albumin? Because of pK_a. A thiol only reacts efficiently in its deprotonated thiolate form, and albumin's cysteine-34 sits in an unusual local environment that drops its pK_a to roughly 5, compared with about 8.5–8.9 for free cysteine and glutathione. At blood pH, Cys34 is overwhelmingly deprotonated and the small-molecule thiols largely are not. Combine that reactivity advantage with albumin's sheer abundance — it is the most plentiful protein in plasma by a wide margin — and the maleimide finds Cys34 with remarkable consistency.

Cys34 is also, conveniently, the only free cysteine on the albumin molecule; all 34 of the others are locked into disulfide bridges. So there is exactly one docking point per albumin molecule, giving a clean, defined 1:1 conjugate rather than a heterogeneous mixture. Once formed, the thioether bond is covalent and durable — the peptide does not simply drift on and off its carrier the way a non-covalent albumin binder would.

Why albumin is the carrier of choice

Albumin is a 66.5 kDa globular protein and the workhorse of plasma. Its natural role is to carry things: fatty acids, hormones, bilirubin, metal ions, and a long list of drugs. Three properties make it close to an ideal half-life-extension vehicle:

It is large enough to escape the kidney. At 66.5 kDa, albumin sits comfortably above the glomerular filtration cutoff. Anything covalently tethered to it is retained by association — the tiny peptide is now, functionally, part of a large protein.

It is actively rescued from degradation. Albumin's long life is not passive. Like antibodies, it is recycled by the neonatal Fc receptor (FcRn): cells take albumin up, and rather than routing it to the lysosome for destruction, FcRn binds it in the acidic endosome and ferries it back out to the bloodstream intact. This salvage pathway is why albumin's circulating half-life in humans runs to roughly three weeks rather than hours.

It goes everywhere. Albumin distributes broadly through plasma and interstitial fluid, so the conjugate is not trapped in a single compartment. And critically for the DAC design, the peptide does not need to be released from albumin to work — it remains accessible to its receptor while still tethered, which is why the linker length matters so much.

One honest caveat: a conjugate cannot outlive its carrier. The peptide's practical duration is bounded by albumin's turnover and by the stability of the thioether bond, which under some conditions can undergo slow exchange. Real-world DAC half-lives land in the range of days — long, but well short of albumin's own three weeks.

In-vivo vs. preformed conjugation

The DAC platform is deployed in two ways, and the distinction shows up in the naming of some compounds.

In-vivo conjugation (DAC). The maleimide-bearing peptide is administered as-is and finds albumin in circulation. This is the classic approach and the one behind CJC-1295 with DAC. Its advantage is simplicity: what is manufactured, purified, and freeze-dried is a small peptide, handled like any other.

Preformed conjugation (PC-DAC). The peptide is reacted with purified or recombinant albumin in the lab first, and the finished peptide–protein complex is what gets administered. This trades manufacturing simplicity for control — you know exactly what the conjugate is before it ever enters a system, rather than relying on the reaction happening correctly in vivo. ConjuChem's exendin-4 program used this route.

For anyone comparing research compounds, the practical point is that a “DAC” peptide in a lyophilized vial is the in-vivo type: the albumin half of the story has not happened yet.

DAC on CJC-1295, in detail

CJC-1295 is the compound that made DAC famous, and it is a good illustration because the molecule shows both halves of modern peptide engineering at once: sequence hardening and carrier attachment.

The starting point is GRF(1–29), the first 29 residues of growth-hormone-releasing hormone — the shortest fragment that retains full activity at the GHRH receptor. Four amino acid substitutions were then made, each fixing a specific chemical weakness:

Those four changes alone produce the short-acting analog widely sold as Modified GRF 1-29 (or “CJC-1295 without DAC”). It is chemically tougher than natural GHRH but still small, still filtered by the kidney, and still measured in minutes rather than days.

The DAC version adds a thirtieth residue — a lysine — and hangs the maleimidopropionyl group off that lysine's side chain. Written out in full, the molecule is N^ε30-maleimidopropionyl-[D-Ala2, Gln8, Ala15, Leu27]-hGRF(1–29)-Lys30. That single addition is worth about 280 daltons of mass — roughly 3,647 Da for the DAC form versus about 3,368 Da for the unmodified analog — and it is the entire difference between the two products.

What that difference bought was documented in humans. In two randomized, placebo-controlled trials in healthy adults published in the Journal of Clinical Endocrinology & Metabolism in 2006, investigators reported an estimated half-life of 5.8 to 8.1 days. After a single subcutaneous administration, mean plasma growth hormone rose 2- to 10-fold for six days or more, and IGF-1 — the downstream mediator through which much of GH's activity is studied — rose 1.5- to 3-fold for nine to eleven days. With repeated administration, IGF-1 remained elevated for as long as 28 days, indicating accumulation. No serious adverse reactions were reported in those trials.

Set those numbers against native GHRH's seven-minute half-life and the scale of what DAC does becomes concrete: roughly a thousand-fold extension of circulating duration, from one chemical group.

Sustained vs. pulsatile signaling

Here is where DAC gets genuinely interesting, and where a lot of casual writing on the topic gets it wrong.

Growth hormone is not secreted at a steady rate. The pituitary releases it in discrete bursts, and that pulsatility is itself biologically meaningful — the pattern of the signal, not just its amount, is read differently by downstream tissue. So the obvious worry with a days-long GHRH signal is that it would flatten the natural rhythm into a continuous drone.

That worry was tested directly. In a 2006 study of healthy men, researchers sampled blood every 20 minutes overnight before and one week after administering CJC-1295. What they found was that pulsatility persisted: the frequency and amplitude of GH secretory pulses were essentially unchanged. What rose sharply was the trough — basal GH between pulses increased about 7.5-fold — with mean GH up roughly 46% and IGF-1 up about 45%.

The mechanistic reading is that a GHRH analog raises the floor without erasing the rhythm, because the rhythm is imposed largely by the opposing hormone somatostatin, which continues to gate release regardless of how much GHRH signal is present. Understanding that shape — elevated baseline, preserved peaks — is the key to understanding why researchers pair DAC compounds with a second peptide, which is the next section.

DAC vs. no-DAC, side by side

Neither form is “better.” They answer different questions, and the choice is a study-design decision rather than a quality one.

Why DAC peptides get mixed with others

Two different things get called “mixing,” and both are worth separating.

1. DAC as a platform applied across peptides. DAC was never designed for CJC-1295 specifically. It is a general half-life-extension technology, and the same maleimide-to-Cys34 trick was applied to entirely unrelated molecules — a GLP-1 analog (CJC-1131) and an exendin-4 analog delivered as a preformed conjugate (CJC-1134-PC) among them. The abbreviation travels with the chemistry, not with the peptide. That is why “DAC” on a label tells you about duration, not about what the compound does.

2. DAC compounds studied alongside a second peptide. This is the pairing most people mean, and the canonical example is a GHRH analog with a growth-hormone-releasing peptide (GHRP) such as Ipamorelin. The rationale is mechanistic and rests on three points:

• Two receptors, one axis. CJC-1295 acts at the GHRH receptor on pituitary somatotrophs. Ipamorelin acts at a completely separate target — the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor — through a phospholipase-C cascade. Stimulating both simultaneously produces a response that is more than the sum of the parts, a synergy documented in the GH-secretagogue literature since the 1990s.
• Complementary kinetics. Recall the shape of the DAC signal: raised baseline, preserved pulses. A GHRP contributes the other half — a sharp, discrete burst. One compound sets the floor, the other builds the peak on top of it. Neither profile alone reproduces that combination.
• Opposing the brake. GHRH analogs push the accelerator, but somatostatin is the brake, and it is what limits how much a GHRH signal alone can achieve. GHRPs act in part by reducing that somatostatin tone. Pairing them means releasing the brake while pressing the pedal — which is a cleaner mechanistic account of the synergy than “two GH peptides are better than one.”

There is also a practical, unglamorous reason blends exist at all: dissolving two peptides separately and matching their concentrations introduces measurement error at every step. A co-lyophilized blend removes that variable. Worth noting — and frequently misunderstood — is that pre-mixed GHRH+GHRP blends typically use the no-DAC form of CJC-1295, precisely because the two compounds are meant to fire together on the same short timescale. Pairing a days-long compound with a minutes-long one in a single vial makes far less sense than pairing two short-acting ones, which is why the DAC version is usually supplied on its own.

What DAC changes at the bench

The albumin chemistry happens in circulation, not in the vial — so in terms of handling, a DAC peptide behaves much like any other lyophilized powder. A few points still deserve attention:

Verification. Because DAC and no-DAC forms are visually identical white powders with confusingly similar names, the Certificate of Analysis is the only real check. Mass spectrometry distinguishes them cleanly: the roughly 280-dalton difference is unmistakable on a spectrum. If a vendor cannot produce a batch-specific COA showing the measured mass, you do not actually know which molecule you have.

Thiol sensitivity. The maleimide group is the whole mechanism, and it is reactive by design. That means it is also the part most worth protecting: reducing agents and thiol-containing buffers will happily consume a maleimide before it ever reaches albumin. Standard cold, dark, dry storage and gentle reconstitution along the vial wall matter here for a concrete chemical reason, not just as general good practice.

Timescale of experiments. A days-long half-life means accumulation across repeated administration — the human data showed IGF-1 still elevated at 28 days with multiple doses. Study designs built around a short-acting analog do not transfer directly; washout periods and sampling schedules have to be scaled to the compound.

Concentration math. Longer duration does not change reconstitution arithmetic, but blends do — a vial containing two peptides has two concentrations to track. Our reconstitution calculator handles the math for both cases.

Status and honest limitations

CJC-1295 with DAC advanced into clinical trials but was never approved as a medicine anywhere; development did not proceed past phase II. The human pharmacokinetic and pulsatility data described above come from that trial program and remain the primary published human evidence base — a small number of studies in healthy adults, now two decades old. Most of what has been published since is preclinical.

That is worth stating plainly because the internet tends to describe DAC compounds with a confidence the literature does not support. The chemistry is well characterized and the pharmacokinetics were measured carefully. The long-term picture was never filled in, because the program stopped. Any research design using these compounds should be built on what was actually shown, not on what the mechanism suggests might follow.

Frequently asked questions

What does DAC stand for in peptides? Drug Affinity Complex. It is a chemical modification — a linker ending in a maleimide group — that bonds the peptide to cysteine-34 on serum albumin, not a peptide in its own right.

How does DAC extend a peptide's half-life? By tethering it to a carrier the body retains. Bound to albumin, the peptide is too large for the kidney to filter and is physically shielded from peptidases; albumin's own three-week circulating life carries the conjugate along with it.

What is the difference between CJC-1295 with and without DAC? The same GHRH-analog core, but with DAC it binds albumin and signals across days; without DAC (Modified GRF 1-29) it is short-acting and produces a brief pulse. Roughly 280 daltons of mass separate them.

Why is a DAC peptide mixed with something like Ipamorelin? Because they hit different receptors — GHRH receptor versus ghrelin receptor — and their signal shapes complement each other: one raises the baseline, the other drives the pulse, while the GHRP also reduces somatostatin's braking effect.

Is DAC used on peptides other than CJC-1295? Yes. It is a general platform that has been applied to GLP-1 and exendin-4 analogs among others. CJC-1295 is simply its best-known application.

Can you tell DAC from no-DAC by looking at the vial? No — both are white lyophilized powders. Only mass spectrometry on a batch-specific COA distinguishes them reliably.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.